Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular events.
The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...
Ventyx Biosciences (VTYX) stock soar as the company announces data from a Phase 2 trial showing the potential of its cardiovascular drug VTX3232. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback